New drug duo takes aim at Hard-to-Treat bladder cancer
NCT ID NCT07241793
First seen Nov 21, 2025 · Last updated Jun 22, 2026 · Updated 28 times
Summary
This Phase II trial tests a targeted drug called trastuzumab rezetecan, alone or with an immunotherapy called adebrelimab, in people with advanced bladder cancer that has a specific protein (HER2). The study aims to see if these treatments can shrink tumors or slow cancer growth. About 96 participants will be enrolled across multiple centers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UROTHELIAL CARCINOMA RECURRENT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jiangxi Cancer Center
RECRUITINGNanchang, Jiangxi, 330000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NOT_YET_RECRUITINGGuangzhou, Guangdong, 510000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sun yat-sen university cancer center
RECRUITINGGuangzhou, Guangdong, 510000, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Second Affiliated Hospital of Kunming Medical University
NOT_YET_RECRUITINGKunming, Yunnan, 650033, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The fifth Affiliated Hospital of Guangzhou Medcial University
RECRUITINGGuangzhou, Guangdong, 510000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tongji Hospital, Affiliated to Tongji Medical College of Huazhong University of Science and Technology
NOT_YET_RECRUITINGWuhan, Hubei, 430030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
trastuzumab rezetecan (a targeted drug) and adebrelimab (an immunotherapy)
What this could lead to
If successful, this could offer a new treatment option for people with advanced bladder cancer that has HER2 protein on its cells.
What could go wrong
This is an early Phase II trial with only 96 people, so results may not apply to everyone. The drugs can cause side effects like infusion reactions or immune-related issues.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.